homovanillic acid has been researched along with Psychoses in 91 studies
Homovanillic Acid: A 3-O-methyl ETHER of (3,4-dihydroxyphenyl)acetic acid.
homovanillate : A hydroxy monocarboxylic acid anion which is obtained by deprotonation of the carboxy group of homovanillic acid.
homovanillic acid : A monocarboxylic acid that is the 3-O-methyl ether of (3,4-dihydroxyphenyl)acetic acid. It is a catecholamine metabolite.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In the preset study, the authors investigated that effects of the antipsychotic drug risperidone on psychotic depression and examined the mechanism of risperidone to ameliorate psychotic depression." | 9.12 | Risperidone in the treatment of psychotic depression. ( Goto, M; Kaji, K; Kakihara, S; Nakamura, J; Shinkai, K; Ueda, N; Yamada, Y; Yoshimura, R, 2006) |
| "In the preset study, the authors investigated that effects of the antipsychotic drug risperidone on psychotic depression and examined the mechanism of risperidone to ameliorate psychotic depression." | 5.12 | Risperidone in the treatment of psychotic depression. ( Goto, M; Kaji, K; Kakihara, S; Nakamura, J; Shinkai, K; Ueda, N; Yamada, Y; Yoshimura, R, 2006) |
| " In this context we carried out a double-blind study of the therapeutic value of clozapine and perphenazine in acute psychoses of varying symptomatology anc aetiology." | 5.04 | Clozapine versus perphenazine: the value of the biochemical mode of action of neuroleptics in predicting their therapeutic activity. ( Dols, LC; Korf, J; Van Praag, HM, 1976) |
| "Metabolism of the monoamines dopamine, serotonin and noradrenaline, is altered in the central nervous system of people with schizophrenia, and their major metabolites homovanillic acid (HVA), 5-hydroxyindoleacetic acid (5-HIAA) and 3-methoxy-4-hydroxyphenylglycol (MHPG), respectively, have been intensively studied as indirect measures of these neurotransmitters in cerebrospinal fluid (CSF)." | 3.88 | No major influence of regular tobacco smoking on cerebrospinal fluid monoamine metabolite concentrations in patients with psychotic disorder and healthy individuals. ( Agartz, I; Andreou, D; Hjärpe, J; Jönsson, EG; Sedvall, GC; Söderman, E, 2018) |
| "In this study, plasma obtained from monozygotic twin pairs discordant for schizophrenia (n = 10) or major affective disorder (n = 3) was assayed for epinephrine, norepinephrine, dihydroxyphenylacetic acid, homovanillic acid, adrencorticotropin hormone, and cortisol." | 3.71 | Plasma hormones and catecholamine metabolites in monozygotic twins discordant for psychosis. ( Bonsall, R; Walder, DJ; Walker, EF, 2002) |
| "Eleven acutely psychotic patients with schizophrenia or schizoaffective disorder underwent a 5-7 day drug-washout period (with lorazepam allowed) prior to participating in a 6-week controlled dose haloperidol trial." | 3.68 | Haloperidol response and plasma catecholamines and their metabolites. ( Alam, MY; Boshes, RA; Fitzgibbon, ME; Green, AI; Pappalardo, KM; Schildkraut, JJ; Tsuang, MT; Waternaux, C, 1993) |
| "Twenty recently admitted patients with mood-incongruent psychoses underwent 1) interviews with the Schedule for Affective Disorders and Schizophrenia for diagnostic evaluation and symptom profiles, 2) drug-free baseline measurements of CSF neurotensin and homovanillic acid, and 3) close monitoring of a therapeutic trial of haloperidol to determine latency of antipsychotic response." | 3.68 | Relation of CSF neurotensin concentrations to symptoms and drug response of psychotic patients. ( Bissette, G; Garver, DL; Nemeroff, CB; Yao, JK, 1991) |
| "The probenecid technique was used in study of the central dopamine DA metabolism in patients with depressions, psychotic disorders, and Parkinson's disease." | 3.65 | Dopamine metabolism in depressions, psychoses, and Parkinson's disease: the problem of the specificity of biological variables in behaviour disorders. ( Korf, J; Praag, HM; Schut, T, 1975) |
| "Psychotic disorders are severe mental disorders with poorly understood etiology." | 3.01 | Biomarkers in the cerebrospinal fluid of patients with psychotic disorders compared to healthy controls: a systematic review and meta-analysis. ( Benros, ME; Christensen, RHB; Jeppesen, R; Rømer, TB, 2023) |
| "Neuropsychiatric symptoms (NPS) in Alzheimer's disease (AD) are present during the disease course of nearly all AD patients and consist of psychosis, agitation/aggression, and depression, among others." | 1.40 | Brain region-specific monoaminergic correlates of neuropsychiatric symptoms in Alzheimer's disease. ( Aerts, T; De Deyn, PP; Engelborghs, S; Van Dam, D; Vermeiren, Y, 2014) |
| "Since delusional disorder is characterized by mono-symptomatic paranoid symptoms, it can be a good clinical model for investigating the dopaminergic mechanism responsible for paranoid symptoms." | 1.31 | Delusional disorder: molecular genetic evidence for dopamine psychosis. ( Hirao, T; Miyatake, R; Morimoto, K; Nakamura, M; Suwaki, H; Watanabe, T, 2002) |
| "These 85 subjects with nonorganic psychoses had been previously studied with respect to their response to neuroleptic treatment." | 1.28 | Characteristics of psychotic inpatients with high or low HVA levels at admission. ( Bowers, MB, 1991) |
| "In the group of 9 children with other psychoses, both the level of homovanillic acid and that of 5-hydroxy-indoleacetic acid was raised." | 1.27 | Childhood psychosis and monoamine metabolites in spinal fluid. ( Gillberg, C; Hamilton-Hellberg, C; Svennerholm, L, 1983) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 44 (48.35) | 18.7374 |
| 1990's | 29 (31.87) | 18.2507 |
| 2000's | 9 (9.89) | 29.6817 |
| 2010's | 7 (7.69) | 24.3611 |
| 2020's | 2 (2.20) | 2.80 |
| Authors | Studies |
|---|---|
| Rømer, TB | 1 |
| Jeppesen, R | 1 |
| Christensen, RHB | 1 |
| Benros, ME | 1 |
| Takase, M | 1 |
| Kimura, H | 1 |
| Kanahara, N | 1 |
| Nakata, Y | 1 |
| Iyo, M | 1 |
| Vingerhoets, C | 1 |
| Bloemen, OJN | 1 |
| Boot, E | 1 |
| Bakker, G | 1 |
| de Koning, MB | 2 |
| da Silva Alves, F | 1 |
| Booij, J | 2 |
| van Amelsvoort, TAMJ | 1 |
| Hjärpe, J | 1 |
| Söderman, E | 3 |
| Andreou, D | 3 |
| Sedvall, GC | 3 |
| Agartz, I | 3 |
| Jönsson, EG | 3 |
| Vermeiren, Y | 1 |
| Van Dam, D | 1 |
| Aerts, T | 1 |
| Engelborghs, S | 1 |
| De Deyn, PP | 1 |
| Axelsson, T | 2 |
| Terenius, L | 2 |
| van de Kerkhof, NW | 1 |
| Fekkes, D | 1 |
| van der Heijden, FM | 1 |
| Egger, JI | 1 |
| Verhoeven, WM | 1 |
| Zumárraga, M | 2 |
| Dávila, R | 2 |
| Basterreche, N | 2 |
| Arrue, A | 2 |
| Goienetxea, B | 1 |
| González-Torres, MA | 1 |
| Guimón, J | 1 |
| Bloemen, OJ | 1 |
| Gleich, T | 1 |
| Meijer, J | 1 |
| de Haan, L | 1 |
| Linszen, DH | 1 |
| van Amelsvoort, TA | 1 |
| Myin-Germeys, I | 1 |
| Marcelis, M | 1 |
| Krabbendam, L | 1 |
| Delespaul, P | 1 |
| van Os, J | 1 |
| Zamalloa, MI | 1 |
| Anguiano, JB | 1 |
| Goto, M | 1 |
| Yoshimura, R | 2 |
| Kakihara, S | 1 |
| Shinkai, K | 1 |
| Yamada, Y | 1 |
| Kaji, K | 1 |
| Ueda, N | 1 |
| Nakamura, J | 2 |
| Ikenouchi, A | 1 |
| Ikemura, N | 1 |
| Utsunomiya, K | 1 |
| Mitoma, M | 1 |
| Bowers, MB | 22 |
| Kantrowitz, JT | 1 |
| Heninger, GR | 2 |
| Sternberg, D | 1 |
| Meltzer, HY | 2 |
| Harris, PQ | 1 |
| Brown, SJ | 1 |
| Friedman, MJ | 1 |
| Bacopoulos, NG | 1 |
| Agnoli, A | 1 |
| Ruggieri, S | 1 |
| Falaschi, P | 1 |
| Baldassarre, M | 1 |
| D'Urso, R | 1 |
| Forchetti, C | 1 |
| Polleri, A | 1 |
| Sedvall, G | 5 |
| Leckman, JF | 1 |
| Sturges, JS | 1 |
| Van Woert, MH | 1 |
| Magnussen, I | 1 |
| Lowe, YH | 1 |
| Hwang, EC | 1 |
| Korf, J | 4 |
| van den Burg, W | 1 |
| van den Hoofdakker, RH | 1 |
| Nybäck, H | 1 |
| Berggren, BM | 1 |
| Hindmarsh, T | 1 |
| Wiesel, FA | 1 |
| Cowdry, RW | 1 |
| Ebert, MH | 1 |
| van Kammen, DP | 1 |
| Post, RM | 1 |
| Goodwin, FK | 2 |
| Gillberg, C | 1 |
| Svennerholm, L | 1 |
| Hamilton-Hellberg, C | 1 |
| Mann, JJ | 1 |
| Stanley, M | 1 |
| Gershon, S | 2 |
| Rossor, M | 1 |
| Swigar, ME | 6 |
| Jatlow, PI | 7 |
| Goicoechea, N | 3 |
| Gold, BI | 1 |
| Roth, RH | 1 |
| Faustman, WO | 1 |
| Ringo, DL | 1 |
| Faull, KF | 3 |
| Kahn, RS | 2 |
| Davidson, M | 3 |
| Knott, P | 1 |
| Stern, RG | 1 |
| Apter, S | 2 |
| Davis, KL | 2 |
| Amin, F | 1 |
| Schmeidler, J | 1 |
| Stern, R | 1 |
| Knott, PJ | 1 |
| Oades, RD | 1 |
| Röpcke, B | 1 |
| Eggers, C | 1 |
| Risby, ED | 1 |
| Jewart, RD | 1 |
| Lewine, RR | 1 |
| Risch, SC | 1 |
| Stipetic, M | 1 |
| McDaniel, JS | 1 |
| Caudle, J | 1 |
| Green, AI | 1 |
| Alam, MY | 1 |
| Boshes, RA | 1 |
| Waternaux, C | 1 |
| Pappalardo, KM | 1 |
| Fitzgibbon, ME | 1 |
| Tsuang, MT | 1 |
| Schildkraut, JJ | 2 |
| Sumiyoshi, T | 1 |
| Hasegawa, M | 1 |
| Jayathilake, K | 1 |
| Maas, JW | 1 |
| Bowden, CL | 1 |
| Miller, AL | 1 |
| Javors, MA | 1 |
| Funderburg, LG | 1 |
| Berman, N | 1 |
| Weintraub, ST | 1 |
| Mazure, CM | 4 |
| Quinlan, DM | 1 |
| Ottong, SE | 1 |
| Garver, DL | 3 |
| Steinberg, JL | 1 |
| McDermott, BE | 1 |
| Yao, JK | 2 |
| Ramberg, JE | 1 |
| Lewis, S | 1 |
| Kingsbury, SJ | 1 |
| Gruen, RJ | 1 |
| Silva, R | 1 |
| Ehrlich, J | 1 |
| Schweitzer, JW | 1 |
| Friedhoff, AJ | 1 |
| Brown, AS | 1 |
| Gewirtz, G | 1 |
| Harkavy-Friedman, J | 1 |
| Cooper, T | 1 |
| Brébion, G | 1 |
| Amador, XF | 1 |
| Malaspina, D | 1 |
| Gorman, JM | 1 |
| Sharma, RP | 3 |
| Javaid, JI | 4 |
| Davis, JM | 4 |
| Janicak, PG | 2 |
| Posener, JA | 1 |
| Schatzberg, AF | 1 |
| Williams, GH | 1 |
| Samson, JA | 1 |
| McHale, NL | 1 |
| Bessette, MP | 1 |
| Poirier, MF | 2 |
| Galinowski, A | 2 |
| Castelnau, C | 1 |
| Spreux-Varoquaux, O | 1 |
| Bourdel, MC | 1 |
| Olie, JP | 1 |
| Loo, H | 1 |
| Walker, EF | 1 |
| Bonsall, R | 1 |
| Walder, DJ | 1 |
| Morimoto, K | 1 |
| Miyatake, R | 1 |
| Nakamura, M | 1 |
| Watanabe, T | 1 |
| Hirao, T | 1 |
| Suwaki, H | 1 |
| Costentin, J | 1 |
| Härnryd, C | 1 |
| Bjerkenstedt, L | 1 |
| Grimm, VE | 1 |
| Klawans, H | 1 |
| van Praag, HM | 2 |
| Crow, TJ | 1 |
| Deakin, JF | 1 |
| Longden, A | 1 |
| Wode-Helgodt, B | 2 |
| Cohen, DJ | 2 |
| Caparulo, BK | 1 |
| Shaywitz, BA | 2 |
| Fyrö, B | 1 |
| Gullberg, B | 1 |
| Markianos, E | 1 |
| Rüther, E | 1 |
| Waldmeier, PC | 1 |
| Maître, L | 1 |
| Dols, LC | 1 |
| Praag, HM | 1 |
| Schut, T | 1 |
| Nelson, JC | 3 |
| Pandey, GN | 2 |
| Lohr, JB | 1 |
| Kuczenski, R | 1 |
| Bracha, HS | 1 |
| Moir, M | 1 |
| Jeste, DV | 1 |
| Jibson, M | 1 |
| Csernansky, JG | 2 |
| Bissette, G | 1 |
| Nemeroff, CB | 1 |
| Easton, M | 1 |
| Breier, A | 1 |
| Wolkowitz, OM | 1 |
| Roy, A | 1 |
| Potter, WZ | 1 |
| Pickar, D | 1 |
| Jennings, WS | 1 |
| Schulz, SC | 1 |
| Narasimhachari, N | 1 |
| Hamer, RM | 1 |
| Friedel, RO | 1 |
| Joborn, C | 1 |
| Hetta, J | 1 |
| Johansson, H | 1 |
| Rastad, J | 1 |
| Agren, H | 1 |
| Akerström, G | 1 |
| Ljunghall, S | 1 |
| Pfefferbaum, A | 1 |
| Sharma, R | 1 |
| Janicak, P | 1 |
| Faull, K | 1 |
| Comaty, J | 1 |
| Hoffman, FJ | 3 |
| Harvey, NS | 1 |
| Kendler, KS | 1 |
| Davis, BM | 1 |
| Horvath, TB | 1 |
| Mohs, RC | 1 |
| Angrist, B | 1 |
| Johnson, WT | 1 |
| Bowers, M | 1 |
| Mattsson, B | 1 |
| Perris, C | 1 |
| Sack, RL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00004325] | 200 participants | Observational | 1988-12-31 | Completed | |||
| Clozapine Response and Biogenic Amines in Schizophrenia[NCT00169039] | Phase 4 | 66 participants | Interventional | 1994-12-31 | Terminated | ||
| Efficacy of Quetiapine in Treating Patients With Active Substance Use Disorder and Schizophrenia[NCT00156715] | Phase 4 | 23 participants (Actual) | Interventional | 2004-03-31 | Completed | ||
| Risperidone Long-Acting for Alcohol and Schizophrenia Treatment (R-LAST)[NCT00130923] | Phase 4 | 95 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The main outcome measure of clinical symptoms was the Positive and Negative Symptoms Scale. This is a 30 item scale for assessing patients diagnosed with schizophrenia. Each item is rated on a 1 (absent) to 7 (extreme) scale. The minimum total score is 30 and the maximum is 210. (NCT00156715)
Timeframe: 12 Weeks
| Intervention | Units on a scale (Mean) |
|---|---|
| QUET | 65.5 |
Timeline Follow-back (TLFB) procedure was used at screening and baseline to establish current substance use, and it was also used weekly during the course of the study to assess continued alcohol and other substance use. TLFB cosisted of using a calendar and sasking participants to report alcohol and other drug use since last visit. At the screening visit, the TLFB was done for the four weeks prior to the visit. (NCT00156715)
Timeframe: 12 Weeks
| Intervention | Drinking Days per Week (Mean) |
|---|---|
| QUET | 2.7 |
Frequency of drinking days is obtained each week retrospectively as the number of drinking days during the prior week (assessed using the Timeline Followback). Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. (NCT00130923)
Timeframe: 6 months
| Intervention | drinking days per week (Number) |
|---|---|
| Risperidone Long Acting Injectable (LAI) | 2.84 |
| Oral Risperidone Aka Risperdal | 3.46 |
A rater assesses social, occupational and psychological functioning on a hypothetical continuum of mental health - illness (using Global Assessment of Functioning); scores range from 100 to 1, where higher values represent a better outcome. Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. (NCT00130923)
Timeframe: 6 months
| Intervention | ordinal severity of impairment (Number) |
|---|---|
| Risperidone Long Acting Injectable (LAI) | 50.8 |
| Oral Risperidone Aka Risperdal | 49.9 |
A rater assesses positive and negative symptoms of schizophrenia using a 30-item scale (Positive and Negative Symptom Score) Scores range from 30 to 210, where higher values represent a worse outcome. Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. (NCT00130923)
Timeframe: 6 months
| Intervention | ordinal severity of symptoms (Number) |
|---|---|
| Risperidone Long Acting Injectable (LAI) | 78.2 |
| Oral Risperidone Aka Risperdal | 75.5 |
A rater assesses the severity of illness and global impression using a scale from 1 to 7 (Clinical Global Impression), where higher values represent a worse outcome. Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. (NCT00130923)
Timeframe: 6 months
| Intervention | ordinal unit of severity (Number) |
|---|---|
| Risperidone Long Acting Injectable (LAI) | 4.02 |
| Oral Risperidone Aka Risperal | 3.96 |
Frequency of heavy drinking days is obtained each week retrospectively as the number of heavy drinking days during the prior week (assessed by the Timeline Followback Scale). A heavy drinking day is defined as 4 or more drinks per day for a female and 5 or more drinks per day for a male. Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. (NCT00130923)
Timeframe: 6 months
| Intervention | heavy drinking days per week (Number) |
|---|---|
| Risperidone Long Acting Injectable (LAI) | -.11 |
| Oral Risperidone Aka Risperal | .68 |
Number of participants with medication adherence (defined as taking medication at least 75% of the days in the treatment period). (NCT00130923)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Risperidone Long Acting Injectable (LAI) | 43 |
| Oral Risperidone Aka Risperdal | 28 |
8 reviews available for homovanillic acid and Psychoses
| Article | Year |
|---|---|
Biomarkers in the cerebrospinal fluid of patients with psychotic disorders compared to healthy controls: a systematic review and meta-analysis.
Topics: Biomarkers; Dopamine; Homovanillic Acid; Humans; Norepinephrine; Psychotic Disorders | 2023 |
Cerebrospinal fluid probenecid studies: a reinterpretation.
Topics: Biological Transport; Brain; Depressive Disorder; Dopamine; Homovanillic Acid; Humans; Hydroxyindole | 1983 |
[Biological approaches to acute psychoses].
Topics: Acute Disease; Antipsychotic Agents; Brain; Cognition Disorders; Homovanillic Acid; Humans; Magnetic | 1999 |
[Modulation of dopaminergic receptor sensitivity in the central nervous system: important parameters in synaptic function regulation].
Topics: Acetylcholine; Adenylyl Cyclases; Animals; Antipsychotic Agents; Apomorphine; Behavior; Corpus Stria | 1979 |
Amine precursors in neurologic disorders and the psychoses.
Topics: Acetylcholine; Corpus Striatum; Dopamine; Homovanillic Acid; Humans; Huntington Disease; Hydroxyindo | 1975 |
Psychiatric disorders in parkinsonism. 1. Functional illnesses and personality.
Topics: Antidepressive Agents; Clozapine; Depressive Disorder; Dopamine; Electroconvulsive Therapy; Female; | 1986 |
Dopamine and psychotic states: preliminary remarks.
Topics: Amphetamine; Animals; Apomorphine; Behavior, Animal; Carbon Radioisotopes; Cats; Cocaine; Dihydroxyp | 1974 |
Central dopamine function in affective illness: evidence from precursors, enzyme inhibitors, and studies of central dopamine turnover.
Topics: Adult; Affective Symptoms; Anger; Bipolar Disorder; Central Nervous System; Depression; Diagnosis, D | 1974 |
14 trials available for homovanillic acid and Psychoses
| Article | Year |
|---|---|
Plasma homovanillic acid and family history of psychotic disorders in bipolar I patients.
Topics: Adult; Antimanic Agents; Benzodiazepines; Bipolar Disorder; Drug Therapy, Combination; Family Health | 2009 |
Striatal dopamine D2/3 receptor binding following dopamine depletion in subjects at Ultra High Risk for psychosis.
Topics: Adult; alpha-Methyltyrosine; Benzamides; Case-Control Studies; Corpus Striatum; Dopamine; Dopamine A | 2013 |
Subtle fluctuations in psychotic phenomena as functional states of abnormal dopamine reactivity in individuals at risk.
Topics: Adult; Disease Susceptibility; Dopamine; Female; Genetic Predisposition to Disease; Homovanillic Aci | 2005 |
Risperidone in the treatment of psychotic depression.
Topics: Adult; Aged; Analysis of Variance; Antidepressive Agents; Antipsychotic Agents; Depression; Dose-Res | 2006 |
Recent life stressors and biological markers in newly admitted psychotic patients.
Topics: Acute Disease; Adolescent; Adult; Antipsychotic Agents; Biomarkers; Female; Homovanillic Acid; Human | 1997 |
Etiologic heterogeneity of the psychoses: is there a dopamine psychosis?
Topics: Adolescent; Adult; Antipsychotic Agents; Family; Female; Haloperidol; Homovanillic Acid; Humans; Mal | 1997 |
Effects of clozapine on plasma catecholamines and relation to treatment response in schizophrenia: a within-subject comparison with haloperidol.
Topics: Aged; Analysis of Variance; Antipsychotic Agents; Clozapine; Haloperidol; Homovanillic Acid; Humans; | 1997 |
Pretreatment plasma homovanillic acid in schizophrenia and schizoaffective disorder: the influence of demographic variables and the inpatient drug-free period.
Topics: Adult; Age of Onset; Brief Psychiatric Rating Scale; Female; Homovanillic Acid; Humans; Male; Psycho | 1998 |
Hypothalamic-pituitary-adrenal axis effects on plasma homovanillic acid in man.
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Adult; Corticotropin-Releasing Hormone; Cross- | 1999 |
Evolution of plasma homovanillic acid (HVA) levels during treatment in schizo-affective disorder.
Topics: Adolescent; Adult; Antidepressive Agents, Tricyclic; Antimanic Agents; Antipsychotic Agents; Chlorpr | 2000 |
Effect of chlorpromazine treatment on monoamine metabolite levels in cerebrospinal fluid of psychotic patients.
Topics: Adult; Aged; Chlorpromazine; Ethylene Glycols; Female; Homovanillic Acid; Humans; Hydroxyindoleaceti | 1977 |
Clozapine versus perphenazine: the value of the biochemical mode of action of neuroleptics in predicting their therapeutic activity.
Topics: Adult; Clozapine; Dibenzazepines; Dopamine; Female; Homovanillic Acid; Humans; Hypnotics and Sedativ | 1976 |
Behavioral and biochemical effects of methylphenidate in schizophrenic and nonschizophrenic patients.
Topics: Adult; Brain; Depressive Disorder; Double-Blind Method; Female; Growth Hormone; Homovanillic Acid; H | 1991 |
Pharmacological effects of methylphenidate on plasma homovanillic acid and growth hormone.
Topics: Adult; Affective Disorders, Psychotic; Blood Pressure; Brain; Double-Blind Method; Female; Growth Ho | 1990 |
69 other studies available for homovanillic acid and Psychoses
| Article | Year |
|---|---|
Plasma monoamines change under dopamine supersensitivity psychosis in patients with schizophrenia: A comparison with first-episode psychosis.
Topics: Adult; Aged; Antipsychotic Agents; Dopamine; Female; Homovanillic Acid; Humans; Male; Methoxyhydroxy | 2020 |
Dopamine in high-risk populations: A comparison of subjects with 22q11.2 deletion syndrome and subjects at ultra high-risk for psychosis.
Topics: Adolescent; Adult; Biomarkers; Case-Control Studies; Corpus Striatum; DiGeorge Syndrome; Dopamine; F | 2018 |
No major influence of regular tobacco smoking on cerebrospinal fluid monoamine metabolite concentrations in patients with psychotic disorder and healthy individuals.
Topics: Adolescent; Adult; Biogenic Monoamines; Biomarkers; Female; Homovanillic Acid; Humans; Hydroxyindole | 2018 |
Brain region-specific monoaminergic correlates of neuropsychiatric symptoms in Alzheimer's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Aged, 80 and over; Alzheimer Disease; Autopsy; Biogenic Monoam | 2014 |
Cerebrospinal fluid monoamine metabolite concentrations as intermediate phenotypes between glutamate-related genes and psychosis.
Topics: Adult; Biogenic Monoamines; Biomarkers; Dopamine; Female; Glutamic Acid; Homovanillic Acid; Humans; | 2015 |
Relationship between plasma homovanillic acid and outcome in patients with psychosis spectrum disorders.
Topics: Adult; Antipsychotic Agents; Female; Homovanillic Acid; Humans; Male; Psychiatric Status Rating Scal | 2015 |
Associations between a locus downstream DRD1 gene and cerebrospinal fluid dopamine metabolite concentrations in psychosis.
Topics: Adult; Dopamine; Female; Genetic Association Studies; Genetic Loci; Homovanillic Acid; Humans; Male; | 2016 |
Influence of the catechol-O-methyltransferase Val108/158Met polymorphism on the plasma concentration of catecholamine metabolites and on clinical features in type I bipolar disorder--a preliminary report.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Biogenic Monoamines; Bipolar Disorder; Catechol O-Meth | 2006 |
Plasma levels of brain derived-neurotrophic factor and catecholamine metabolites are increased during active phase of psychotic symptoms in CNS lupus: a case report.
Topics: Adult; Brain-Derived Neurotrophic Factor; Catecholamines; Homovanillic Acid; Humans; Immunosuppressi | 2006 |
Elevated plasma dopamine metabolites in cannabis psychosis.
Topics: Adult; Brief Psychiatric Rating Scale; Dopamine; Homovanillic Acid; Humans; Marijuana Abuse; Psychos | 2007 |
Clinical processes and central dopaminergic activity in psychotic disorders.
Topics: Adolescent; Adult; Antipsychotic Agents; Dopamine; Female; gamma-Aminobutyric Acid; Homovanillic Aci | 1980 |
Cerebrospinal fluid homovanillic acid patterns during neuroleptic treatment.
Topics: Adult; Antipsychotic Agents; Chlorpromazine; Female; Haloperidol; Homovanillic Acid; Humans; Male; P | 1981 |
Family history and CSF homovanillic acid pattern during neuroleptic treatment.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Female; Homovanillic Acid; Hospitalization; Hos | 1984 |
Plasma drug and homovanillic acid levels in psychotic patients receiving neuroleptics.
Topics: Animals; Antipsychotic Agents; Cattle; Caudate Nucleus; Chromatography, High Pressure Liquid; Dose-R | 1984 |
A neuropharmacological and neuroendocrine study on idiopathic and chronic pharmacological Parkinsonism.
Topics: Adult; Aged; Antipsychotic Agents; Chronic Disease; Circadian Rhythm; Homovanillic Acid; Humans; Hyd | 1980 |
Concentrations of monoamine metabolites and chlorpromazine in cerebrospinal fluid for prediction of therapeutic response in psychotic patients treated with neuroleptic drugs.
Topics: Antipsychotic Agents; Chlorpromazine; Glycols; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; | 1980 |
Relationship between estimated premorbid adjustment and CSF homovanillic acid and 5-hydroxyindoleacetic acid levels.
Topics: Adolescent; Adult; Affective Disorders, Psychotic; Aged; Female; Homovanillic Acid; Humans; Hydroxyi | 1981 |
Study of serotonin in neuropsychiatric disorders.
Topics: 5-Hydroxytryptophan; Carbidopa; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Kinetic | 1982 |
Acid metabolites and precursor amino acids of 5-hydroxytryptamine and dopamine in affective and other psychiatric disorders.
Topics: Adjustment Disorders; Adult; Aged; Amino Acids; Bipolar Disorder; Depressive Disorder; Dopamine; Fem | 1983 |
Cerebroventricular size and cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy volunteers.
Topics: Adult; Age Factors; Cerebral Ventriculography; Female; Homovanillic Acid; Humans; Hydroxyindoleaceti | 1983 |
Childhood psychosis and monoamine metabolites in spinal fluid.
Topics: Adolescent; Age Factors; Autistic Disorder; Brain Diseases; Cerebral Palsy; Child; Child, Preschool; | 1983 |
Mental symptoms in Huntington's disease and a possible primary aminergic neuron lesion.
Topics: Basal Ganglia; Cerebral Cortex; Dopamine; Female; Homovanillic Acid; Humans; Huntington Disease; Mal | 1980 |
Plasma catecholamine metabolites and early response to haloperidol.
Topics: Acute Disease; Adolescent; Adult; Female; Glycols; Haloperidol; Homovanillic Acid; Hospitalization; | 1984 |
CSF GABA in psychotic disorders.
Topics: Adolescent; Adult; Female; gamma-Aminobutyric Acid; Haloperidol; Homovanillic Acid; Humans; Male; Mi | 1980 |
Sex differences in plasma homovanillic acid in acute psychosis.
Topics: Acute Disease; Adolescent; Adult; Female; Haloperidol; Homovanillic Acid; Humans; Male; Middle Aged; | 1983 |
An association between low levels of 5-HIAA and HVA in cerebrospinal fluid and early mortality in a diagnostically mixed psychiatric sample.
Topics: Adult; Aged; Cause of Death; Depressive Disorder; Follow-Up Studies; Homovanillic Acid; Hospital Rec | 1993 |
Effect of neuroleptic medication on cerebrospinal fluid monoamine metabolite concentrations in schizophrenia. Serotonin-dopamine interactions as a target for treatment.
Topics: Adult; Dopamine; Haloperidol; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Male; Psychiatric | 1993 |
Assessment of the central dopaminergic index of plasma HVA in schizophrenia.
Topics: Brain; Debrisoquin; Dopamine; Homovanillic Acid; Humans; Male; Methoxyhydroxyphenylglycol; Neurons; | 1995 |
Monoamine activity reflected in urine of young patients with obsessive compulsive disorder, psychosis with and without reality distortion and healthy subjects: an explorative analysis.
Topics: Adolescent; Adult; Antipsychotic Agents; Brief Psychiatric Rating Scale; Creatinine; Dopamine; Epine | 1994 |
Psychotic patients with increased plasma HVA and MHPG or increased HVA alone.
Topics: Adult; Arousal; Female; Homovanillic Acid; Humans; Male; Methoxyhydroxyphenylglycol; Psychiatric Sta | 1993 |
An association between increased concentrations of cerebrospinal fluid dopamine sulfate and higher negative symptom scores in patients with schizophrenia and schizoaffective disorder.
Topics: Chronic Disease; Dopamine; Homovanillic Acid; Humans; Psychiatric Status Rating Scales; Psychotic Di | 1993 |
Haloperidol response and plasma catecholamines and their metabolites.
Topics: Adult; Catecholamines; Dopamine; Female; Haloperidol; Homovanillic Acid; Humans; Longitudinal Studie | 1993 |
Haloperidol response and plasma catecholamines and their metabolites.
Topics: Adult; Catecholamines; Dopamine; Female; Haloperidol; Homovanillic Acid; Humans; Longitudinal Studie | 1993 |
Haloperidol response and plasma catecholamines and their metabolites.
Topics: Adult; Catecholamines; Dopamine; Female; Haloperidol; Homovanillic Acid; Humans; Longitudinal Studie | 1993 |
Haloperidol response and plasma catecholamines and their metabolites.
Topics: Adult; Catecholamines; Dopamine; Female; Haloperidol; Homovanillic Acid; Humans; Longitudinal Studie | 1993 |
Sex differences in plasma homovanillic acid levels in schizophrenia and normal controls: relation to neuroleptic resistance.
Topics: Antipsychotic Agents; Female; Homovanillic Acid; Humans; Male; Prolactin; Psychiatric Status Rating | 1997 |
Schizophrenia, psychosis, and cerebral spinal fluid homovanillic acid concentrations.
Topics: Adult; Aged; Brain; Dopamine; Homovanillic Acid; Humans; Male; Middle Aged; Psychiatric Status Ratin | 1997 |
A biomodal distribution of plasma HVA/MHPG in the psychoses.
Topics: Adult; Female; Homovanillic Acid; Humans; Male; Methoxyhydroxyphenylglycol; Psychotic Disorders; Sch | 1997 |
Plasma HVA and MHPG in psychiatric patients with renal failure and levodopa-treated Parkinson's disease.
Topics: Adult; Aged; Depressive Disorder; Female; Homovanillic Acid; Humans; Kidney Failure, Chronic; Levodo | 1996 |
Vulnerability to stress: self-criticism and stress-induced changes in biochemistry.
Topics: Adult; Chromatography, High Pressure Liquid; Circadian Rhythm; Female; Homovanillic Acid; Humans; Ps | 1997 |
[The concept of schizoaffective disorder: paraclinical validity of schizoaffective disorder].
Topics: Delirium; Depression; Homovanillic Acid; Humans; Monoamine Oxidase; Psychiatric Status Rating Scales | 1999 |
Plasma hormones and catecholamine metabolites in monozygotic twins discordant for psychosis.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adolescent; Adrenocorticotropic Hormone; Adult; Bipolar Disorder; Ca | 2002 |
Delusional disorder: molecular genetic evidence for dopamine psychosis.
Topics: Adult; Antipsychotic Agents; Female; Genotype; Homovanillic Acid; Humans; Male; Middle Aged; Psychot | 2002 |
Reduction of MOPEG levels in cerebrospinal fluid of psychotic women after electroconvulsive treatment.
Topics: Biogenic Amines; Electroconvulsive Therapy; Female; Glycols; Homovanillic Acid; Humans; Hydroxyindol | 1979 |
Biochemical research into psychosis.
Topics: Brain; Catecholamines; Chlorpromazine; Depression, Chemical; Dopamine; Drug Evaluation; Haloperidol; | 1975 |
The nucleus accumbens--possible site of antipsychotic action of neuroleptic drugs?
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Benztropine; Chlorpromazine; Corpus Striatum; Dopamine; Dos | 1977 |
CSF acid monoamine metabolites in psychotic syndromes: what might they signify?
Topics: Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Phenylacetates; Prognosis; Psychotic Disorders; | 1978 |
Correlations between height of subject and concentrations of monoamine metabolites in cerebrospinal fluid from psychotic men and women.
Topics: Biogenic Amines; Body Height; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Male; Met | 1978 |
Dopamine and serotonin metabolism in neuropsychiatrically disturbed children. CSF homovanillic acid and 5-hydroxyindoleacetic acid.
Topics: Adolescent; Age Factors; Aphasia; Attention Deficit Disorder with Hyperactivity; Autistic Disorder; | 1977 |
Gas chromatographic estimation of homovanillic acid in serum of normals and psychotic patients.
Topics: Chromatography, Gas; Homovanillic Acid; Humans; Phenylacetates; Psychotic Disorders | 1976 |
On the relevance of preferential increases of mesolimbic versus striatal dopamine turnover for the prediction of antipsychotic activity of psychotropic drugs.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Anthracenes; Clozapine; Corpus Striatum; Dopamine; Dose-Res | 1976 |
Dopamine metabolism in depressions, psychoses, and Parkinson's disease: the problem of the specificity of biological variables in behaviour disorders.
Topics: Adjustment Disorders; Bipolar Disorder; Brain; Carboxy-Lyases; Depression; Dihydroxyphenylalanine; D | 1975 |
Serotonin (5HT) systems in psychotic states.
Topics: Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Probenecid; Psychotic Disorders; Serotonin; Tim | 1975 |
Lithium in combination with perphenazine: effect on plasma monoamine metabolites.
Topics: Adult; Aged; Bipolar Disorder; Drug Therapy, Combination; Female; Homovanillic Acid; Humans; Lithium | 1992 |
Characteristics of psychotic inpatients with high or low HVA levels at admission.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Female; Gas Chromatography-Mass Spectrometry; Homovan | 1991 |
Increased indices of free radical activity in the cerebrospinal fluid of patients with tardive dyskinesia.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Aged; Antipsychotic Agents; Dyskinesia, Drug-Induced; Female; | 1990 |
Intercorrelations among monoamine metabolite concentrations in human lumbar CSF are not due to a shared acid transport system.
Topics: Acid-Base Equilibrium; Administration, Oral; Blood-Brain Barrier; Depressive Disorder; Dose-Response | 1990 |
Plasma free homovanillic acid (HVA) as a predictor of clinical response in acute psychosis.
Topics: Acute Disease; Adolescent; Adult; Bipolar Disorder; Chromatography, High Pressure Liquid; Depressive | 1991 |
Psychotogenic drug use and neuroleptic response.
Topics: Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder; Haloperidol; Homovan | 1990 |
Psychotogenic drug use and neuroleptic response.
Topics: Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder; Haloperidol; Homovan | 1990 |
Psychotogenic drug use and neuroleptic response.
Topics: Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder; Haloperidol; Homovan | 1990 |
Psychotogenic drug use and neuroleptic response.
Topics: Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder; Haloperidol; Homovan | 1990 |
Relation of CSF neurotensin concentrations to symptoms and drug response of psychotic patients.
Topics: Adult; Female; Haloperidol; Homovanillic Acid; Humans; Lithium; Male; Middle Aged; Neurotensin; Psyc | 1991 |
Plasma norepinephrine in chronic schizophrenia.
Topics: Adult; Chronic Disease; Female; Homovanillic Acid; Humans; Male; Norepinephrine; Posture; Psychiatri | 1990 |
Brain ventricular size and CSF monoamine metabolites in an adolescent inpatient population.
Topics: Adolescent; Adult; Age Factors; Cerebral Ventricles; Child; Dilatation, Pathologic; Female; Homovani | 1985 |
Psychiatric morbidity in primary hyperparathyroidism.
Topics: Adult; Aged; Calcium; Female; Follow-Up Studies; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid | 1988 |
Seasonal changes of CSF monoamine metabolites in psychiatric patients: what is the source?
Topics: Bipolar Disorder; Depressive Disorder; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Mental D | 1988 |
Plasma and CSF HVA before and after pharmacological treatment.
Topics: Adult; Brain; Desipramine; Female; Homovanillic Acid; Humans; Lithium; Male; Psychiatric Status Rati | 1989 |
Plasma catecholamine metabolites and treatment response at neuroleptic steady state.
Topics: Adolescent; Adult; Aged; Female; Glycols; Haloperidol; Homovanillic Acid; Humans; Male; Methoxyhydro | 1989 |
Characteristics of patients with the highest plasma catecholamine metabolite levels.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Depressive Disorder; Feeding and Eating Disorders; Femal | 1988 |
Correlates of early neuroleptic response using a uniform haloperidol dose.
Topics: Adult; Aged; Female; Haloperidol; Homovanillic Acid; Humans; Male; Methoxyhydroxyphenylglycol; Middl | 1987 |
Acute psychosis and plasma catecholamine metabolites.
Topics: Adult; Age Factors; Fasting; Female; Glycols; Homovanillic Acid; Hospitalization; Humans; Male; Meth | 1987 |
Apomorphine has no effect on plasma homovanillic acid in schizophrenic patients.
Topics: Adult; Apomorphine; Haloperidol; Homovanillic Acid; Humans; Male; Middle Aged; Psychotic Disorders; | 1985 |
Biogenic amines in autistic and atypical children. Cerebrospinal fluid measures of homovanillic acid and 5-hydroxyindoleacetic acid.
Topics: Autistic Disorder; Brain; Child; Child, Preschool; Diagnosis, Differential; Dopamine; Electroencepha | 1974 |
Average evoked responses (AER) and homovanillic acid (HVA) in cerebrospinal fluid (CSF) in a psychotic patient with Addison's disease.
Topics: Addison Disease; Adult; Cortisone; Electroconvulsive Therapy; Evoked Potentials; Haloperidol; Homova | 1974 |